BCR-ABL1 kinase-dependent alteration of mRNA metabolism: Potential alternatives for therapeutic intervention

Leukemia and Lymphoma

Volumn 52, Issue SUPPL. 1, 2011, Pages 30-44

  Perrotti, Danilo ^a   Harb, Jason G ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

blast crisis; Myeloid leukemias and dysplasias; RNA binding proteins

Indexed keywords

BCR ABL PROTEIN; BOSUTINIB; DASATINIB; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; IMATINIB; LA ANTIBODY; MESSENGER RNA; MICRORNA; MYC PROTEIN; NILOTINIB; PROTEIN MDM2; PROTEIN P53; RNA BINDING PROTEIN;

BLAST CELL CRISIS; BLAST TRANSFORMATION; CHRONIC MYELOID LEUKEMIA; COLONY FORMING UNIT GM; HUMAN; MUTATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; RNA METABOLISM; RNA PROCESSING; RNA TRANSLATION;

ANTINEOPLASTIC AGENTS; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICRORNAS; RNA, MESSENGER; RNA-BINDING PROTEINS;

EID: 79951501714     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.546914     Document Type: Review

References (122)

1. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004;103:4010-4022. (Pubitemid 38685338)
2. Kantarjian HM, Keating MJ, Talpaz M, et al. Chronic myelogenous leukemia in blast crisis-analysis of 242 patients. Am J Med 1987;83:445-454.
3. Pui L, Liu J, Gish G, et al. Bcr-Abl oncoproteins bind directly to activators of the Ras signaling pathway. EMBO J 1994;13:764-773. (Pubitemid 24057507)
4. Griffin JD. Phosphatidyl inositol signaling by BCR/ABL: opportunities for drug development. Cancer Chemother Pharmacol 2001;48:S11-S16. (Pubitemid 33738365)
5. Coppo P, Flamant S, De Mas V, et al. BCR-ABL activates STAT3 via JAK and MEK pathways in human cells. Br J Haematol 2006;134:171-179. (Pubitemid 43893908)
6. Ilaria RL, VanEtten RA. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 1996;271:31704-31710.
7. Shuai K, Halpern J, tenHoeve J, Rao XP, Sawyers CL. Constitutive activation of STAT5 by the BCR-ABL onco-gene in chronic myelogenous leukemia. Oncogene 1996; 13:247-254. (Pubitemid 26334856)
8. Perrotti D, Jamieson CHM, Goldman J, Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest 2010;120:2254-2264.
9. Stoklosa T, Poplawski T, Koptyra M, et al. BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations. Cancer Res 2008;68:2576-2580. (Pubitemid 351556254)
10. Feinstein E, Cimino G, Gale RP, et al. p53 in chronic myelogenous leukemia in acute phase. Proc Natl Acad Sci USA 1991;88:6293-6297. (Pubitemid 21914932)
11. Zhang SJ, Shi JY, Li JY. GATA-2 L359 V mutation is exclusively associated with CML progression but not other hematological malignancies and GATA-2 P250A is a novel single nucleotide polymorphism. Leuk Res 2009;33:1141-1143.
12. Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of IKAROS. Nature 2008;453:110-114. (Pubitemid 351630327)
13. Cramer K, Nieborowska-Skorska M, Koptyra M, et al. BCR/ABL and other kinases from chronic myeloproliferative dis-orders stimulate single-strand annealing, an unfaithful DNA double-strand break repair. Cancer Res 2008;68:6884-6888.
14. Elmaagacli AH, Beelen DW, Opalka B, Seeber S, Schafer UW. The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage. Ann Hematol 2000;79:424-431. (Pubitemid 30636258)
15. Gaiger A, Henn T, Horth E, et al. Increase of Bcr-Abl chimeric messenger-RNA expression in tumor-cells of patients with chronic myeloid-leukemia precedes disease progression. Blood 1995;86:2371-2378.
16. Jamieson CHM, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004;351:657-667. (Pubitemid 39063268)
17. Neviani P, Santhanam R, Trotta R, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005;8:355-368. (Pubitemid 41579831)
18. Perrotti D, Cesi V, Trotta R, et al. BCR-ABL suppresses C/EBP alpha expression through inhibitory action of hnRNP E2. Nat Genet 2002;30:48-58.
19. Schultheis B, Szydlo R, Mahon FX, Apperley JF, Melo JV. Analysis of total phosphotyrosine levels in CD34(+) cells from CML patients to predict the response to imatinib mesylate treatment. Blood 2005;105:4893-4894. (Pubitemid 40807320)
20. Trotta R, Vignudelli T, Candini O, et al. BCR/ABL activates mdm2 rnRNA translation via the La antigen. Cancer Cell 2003;3:145-160. (Pubitemid 37443387)
21. Nieborowska-Skorska M, Koptyra M, Hoser G, et al. Mechanisms generating free radicals in CML stem/progenitor cell populations causing DNA damage and genomic instability. Blood 2008;112:78-79.
22. Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadel-phia chromosome-positive acute lymphoid leukemias. Blood 2002;100:1965-1971. (Pubitemid 35001224)
23. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99: 3530-3539. (Pubitemid 34534519)
24. Van Etten RA. Oncogenic signaling: new insights and controversies from chronic myeloid leukemia. J Exp Med 2007;204:461-465. (Pubitemid 46457069)
25. Laudadio J, Deininger MWN, Mauro MJ, Druker BJ, Press RD. An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy. J Mol Diagn 2008;10:177-180. (Pubitemid 351428400)
26. Nardi V, Azam M, Daley GQ. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol 2004;11:35-43. (Pubitemid 38021719)
27. Klein F, Feldhahn N, Herzog S, et al. BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells. Oncogene 2006;25: 1118-1124. (Pubitemid 43277019)
28. Salesse S, Dylla SJ, Verfaillie C. p210(BCRABL)-induced alteration of pre-mRNA splicing in primary human CD34(+) hematopoietic progenitor cells. Leukemia 2004;18:727-733. (Pubitemid 38500190)
29. Bhatia R, Munthe HA, Verfaillie CM. Role of abnormal integrin- cytoskeletal interactions in impaired beta 1 integrin function in chronic myelogenous leukemia hematopoietic progenitors. Exp Hematol 1999;27:1384-1396. (Pubitemid 29409457)
30. Salgia R, Li JL, Ewaniuk DS, et al. BCR/ABL induces multiple abnormalities ofcytoskeletal function. J Clin Invest 1997;100:46-57. (Pubitemid 27311242)
31. Bhatia R, McCarthy JB, Verfaillie CM. Interferon-alpha restores normal beta 1 integrin-mediated inhibition ofhema-topoietic progenitor proliferation by the marrow microenvir-onment in chronic myelogenous leukemia. Blood 1996;87: 3883-3891. (Pubitemid 26129618)
32. Verfaillie CM, McCarthyJB, McGlave PB. Differentiation of primitive human multipotent hematopoietic progenitors into single lineage clonogenic progenitors is accompanied by alterations in their interaction with fibronectin. J Exp Med 1991;174:693-703.
33. Abrahamsson AE, Geron I, Gotlib J, et al. Glycogen synthase kinase 3 beta missplicing contributes to leukemia stem cell generation. Proc Natl Acad Sci USA 2009;106:3925-3929.
34. Zhao C, Blum J, Chen A, et al. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 2007;12:528-541. (Pubitemid 350199070)
35. Kharas MG, Fruman DA. ABL oncogenes and phosphoi-nositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res 2005;65:2047-2053. (Pubitemid 40490106)
36. Kharas MG, Janes MR, Scarfone VM, et al. Ablation ofPI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTORinhibitorprevents expansion ofhuman BCR-ABL(+) leukemia cells. J Clin Invest 2008;118:3038-3050.
37. Ren SY, Xue F, Feng J, Skorski T. Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phosphatidylinositol-3 kinase and the protein network of BCRABL oncogenic tyrosine kinase. Exp Hematol 2005; 33:1222-1228. (Pubitemid 41416971)
38. Ly C, Arechiga AF, Melo JV, Walsh CM, Ong ST. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Res 2003;63: 5716-5722. (Pubitemid 37187466)
39. Mohi MG, Boulton C, Gu TL, et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci USA 2004;101:3130-3135. (Pubitemid 38327746)
40. Parmar S, SmithJ, Sassano A, et al. Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFN alpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells. Blood 2005;106:2436-2443. (Pubitemid 41510818)
41. Markova B, Albers C, Breitenbuecher F, et al. Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma 1-driven activation of mTOR/p70S6-kinase pathway. Oncogene 2010;29:739-751.
42. Loewith R, Jacinto E, Wullschleger S, et al. Two TOR com-plexes, only one ofwhich is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 2002;10:457-468. (Pubitemid 35284167)
43. Gingras AC, Raught B, Gygi SP, et al. Hierarchical phosphorylation ofthe translation inhibitor 4E-BP1. Genes Dev 2001;15:2852-2864. (Pubitemid 33042055)
44. Hay N, Sonenberg N. Upstream and downstream of mTOR Genes Dev 2004;18:1926-1945. (Pubitemid 39071573)
45. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTORpathway. Curr Opin Cell Biol 2005;17:596-603.
46. Gingras AC, Raught B, Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators oftranslation. Annu RevBiochem 1999;68:913-963. (Pubitemid 29449212)
47. Lim S, Saw TY, Chuah C, Ong ST. Overexpression and phosphorylation of eIF4E is required for beta-catenin activation in blast crisis chronic myelogenous leukemia. Blood 2009;114:22.
48. Prabhu S, Saadat D, Zhang M, Halbur L, FruehaufJP, Ong ST. A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation. Oncogene 2007;26:1188-1200.
49. Janes MR, Limon JJ, So LM, et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 2010;16:205-213.
50. Zhang M, Fu WX, Prabhu S, et al. Inhibition of polysome assembly enhances imatinib activity against chronic myelo-genous leukemia and overcomes imatinib resistance. Mol Cell Biol 2008;28:6496-6509.
51. Altman JK, Yoon P, Katsoulidis E, et al. Regulatory effects of mammalian target of rapamycin-mediated signals in the generation of arsenic trioxide responses. J Biol Chem 2008;283:1992-2001.
52. Mayerhofer M, Valent P, Sperr WR, Griffin JD, Sillaber C. BCR/ABL induces expression ofvascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1 alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 2002;100:3767-3775. (Pubitemid 35303950)
53. Bellamy WT, Richter L, Sirjani D, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia pro-genitor formation in myelodysplastic syndromes. Blood 2001;97:1427-1434. (Pubitemid 32183769)
54. Glick D, Barth S, Macleod KF. Autophagy: cellular and molecular mechanisms. J Pathol 2010;221:3-12.
55. Klionsky DJ. Autophagy: from phenomenology to molecular understanding in less than a decade. Nat Rev Mol Cell Biol 2007;8:931-937. (Pubitemid 47622558)
56. Kroemer G, Jaattela M. Lysosomes and autophagy in cell death control. Nat Rev Cancer 2005;5:886-897. (Pubitemid 41746033)
57. Baehrecke EH. Autophagy: DUAL roles in life and death? Nat Rev Mol Cell Biol 2005;6:505-510. (Pubitemid 40780562)
58. Kondo Y, Kanzawa T, Sawaya R, Kondo S. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 2005;5:726-734. (Pubitemid 41486365)
59. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007;8:741-752. (Pubitemid 47312826)
60. Lum JJ, Bauer DE, Kong M, et al. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 2005;120:237-248. (Pubitemid 40174766)
61. Bellodi C, Lidonnici MR, Hamilton A, et al. Targeting auto-phagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CMLstem cells. J Clin Invest 2009;119:1109-1123.
62. Dreyfuss G, Kim VN, Kataoka N. Messenger-RNA-binding proteins and the messages they carry. Nat Rev Mol Cell Biol 2002;3:195-205.
63. Keene JD. Ribonucleoprotein infrastructure regulating the flow of genetic information between the genome and the proteome. Proc Natl Acad Sci USA 2001;98:7018-7024. (Pubitemid 32567896)
64. Keene JD, Tenenbaum SA. Eukaryotic mRNPs may repre-sent posttranscriptional operons. Mol Cell 2002;9:1161-1167. (Pubitemid 34722296)
65. Perrotti D, Calabretta B. Post-transcriptional mechanisms in BCRABL leukemogenesis: role of shuttling RNA-binding proteins. Oncogene 2002;21:8577-8583. (Pubitemid 36084190)
66. Perrotti D, Turturro F, Neviani P. BCR/ABL, mRNA tran-slation and apoptosis. Cell Death Differ 2005;12:534-540.
67. Notari M, Neviani P, Santhanam R, et al. A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulat-ing MYC mRNA translation. Blood 2006;107:2507-2516. (Pubitemid 43345575)
68. Perrotti D, Bonatti S, Trotta R, et al. TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCRABL-mediated leukemogenesis. EMBO J 1998;17:4442-4455. (Pubitemid 28362633)
69. Iervolino A, Santilli G, Trotta R, et al. hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesis. Mol Cell Biol 2002;22:2255-2266. (Pubitemid 34224631)
70. Guerzoni C, Bardini M, Mariani SA, et al. Inducible activation of CEBPB, a gene negatively regulated by BCR/ABL, inhibits proliferation and promotes differentiation of BICRABL-expressing cells. Blood 2006;107:4080-4089. (Pubitemid 43726817)
71. Dreyfuss G, Matunis MJ, Pinolroma S, Burd CG. Hnrnp proteins and the biogenesis of messenger-RNA. Annu Rev Biochem 1993;62:289-321.
72. Guil S, Caceres JF. The multifunctional RNA-binding protein hnRNP A1 is required for processing of miR-18a. Nat Struct Mol Biol 2007;14:591-596. (Pubitemid 47037061)
73. Venturini L, Battmer K, Castoldi M, et al. Expression ofthe miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34(+) cells. Blood 2007;109:4399-4405. (Pubitemid 46743409)
74. Eiring AM, Neviani P, Santhanam R, et al. Identification of novel posttranscriptional targets of the BCR/ABL oncopro-tein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis. Blood 2008;111:816-828.
75. Neviani P, Santhanam R, Oaks JJ, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lym-phocytic leukemia. J Clin Invest 2007;117:2408-2421. (Pubitemid 47494343)
76. Vera J, Jaumot M, Estanyol JM, Brun S, Agell N, Bachs O. Heterogeneous nuclear ribonucleoprotein A2 is a SET-binding protein and a PP2A inhibitor. Oncogene 2006; 25:260-270. (Pubitemid 43083687)
77. Perrotti D, Neviani P. From mRNA metabolism to cancer therapy: chronic myelogenous leukemia shows the way. Clin Cancer Res 2007;13:1638-1642. (Pubitemid 46952928)
78. Sawyers CL, Callahan W, Witte ON. Dominant negative Myc blocks transformation by Abl oncogenes. Cell 1992; 70:901-910.
79. Evans JR, Mitchell SA, Spriggs KA, et al. Members ofthe poly (rC) binding protein family stimulate the activity of the c-myc internal ribosome entry segment in vitro and in vivo. Oncogene 2003;22:8012-8020. (Pubitemid 37175865)
80. Michelotti EF, Michelotti GA, Aronsohn AI, Levens D. Heterogeneous nuclear ribonucleoprotein K is a transcrip-tion factor. Mol Cell Biol 1996;16:2350-2360. (Pubitemid 26123756)
81. Gopal V, Kadam P, Preisler H, et al. Abnormal regulation of the Myc gene in myeloid-leukemia. Med Oncol Tumor Pharmacother 1992;9:139-147. (Pubitemid 23067288)
82. Park YG, Zhao XH, Lesueur F, et al. Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Nat Genet 2005;37:1055-1062. (Pubitemid 41486657)
83. Naarmann IS, Harnisch C, Flach N, et al. mRNA silencing in human erythroid cell maturation-heterogeneous nuclear ribonucleoprotein K controls the expression of its regulator c-Src. J Biol Chem 2008;283:18461-18472.
84. Wolin SL, Cedervall T. The LA protein. Annu Rev Biochem 2002;71:375-403. (Pubitemid 34800225)
85. Honda H, Ushijima T, Wakazono K, et al. Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expres-sing hematopoietic cells: a transgenic study for blast crisis of human CML. Blood 2000;95:1144-1150. (Pubitemid 30099819)
86. Skorski T, NieborowskaSkorska M, Wlodarski P, et al. Blastic transformation ofp53-deficient bone marrow cells by p210(bcr/abl) tyrosine kinase. Proc Natl Acad Sci USA 1996;93:13137-13142.
87. Aichberger KJ, Mayerhofer M, Florian S, et al. BCR/ABL-dependent expression of Mcl-1 involves the MAP-kinase pathway and contributes to survival ofleukemic cells. Blood 2003;102(Suppl. 1):Abstract 4987.
88. Aichberger KJ, Mayerhofer M, Krauth MT, et al. Identifica-tion of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileu-kemic effects of imatinib and mcl-1 antisense oligonucleo-tides. Blood 2005;105:3303-3311.
89. Fukuchi Y, Kizaki H, Yamato K, et al. Mcl-1, an early-induction molecule, modulates activin A-induced apoptosis and differentiation of CML cells. Oncogene 2001;20:704-713. (Pubitemid 32179339)
90. Keeshan K, Santilli G, Corradini F, Perrotti D, Calabretta B. Transcription activation function of C/EBP alpha is required for induction of granulocytic differentiation. Blood 2003; 102:1267-1275. (Pubitemid 36988032)
91. Tenen DG. Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer 2003;3:89-101. (Pubitemid 37328876)
92. Ostareck-Lederer A, Ostareck DH. Control of mRNA translation and stability in haematopoietic cells: The function of hnRNPs K and E1/E2. Biol Cell 2004;96: 407-411. (Pubitemid 39157944)
93. Chang JS, Santhanam R, Trotta R, et al. High levels ofthe BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation. Blood 2007;110:994-1003. (Pubitemid 47267439)
94. Wagner K, Zhang P, Rosenbauer F, et al. Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr/abl-induced malignancy. Proc Natl Acad Sci USA 2006; 103:6338-6343.
95. Perrotti D, Marcucci G, Caligiuri MA. Loss of C/EBP alpha and favorable prognosis of acute myeloid leukemias: a biological paradox. J Clin Oncol 2004;22:582-584. (Pubitemid 41095058)
96. Waggoner SA, Johannes GJ, Liebhaber SA. Depletion of the poly(C)-binding proteins alpha CP1 and alpha CP2 from K562 cells leads to p53-independent induction of cyclin-dependent kinase inhibitor (CDKN1A) and G1 arrest. J Biol Chem 2009;284:9039-9049.
97. Jones LC, Lin ML, Chen SS, et al. Expression of C/EBPbeta from the C/ebpalpha gene locus is sufficient for normal hematopoiesis in vivo. Blood 2002;99:2032-2036. (Pubitemid 34525485)
98. Timchenko NA, Welm AL, Lu XH, Timchenko LT. CUG repeat binding protein (CUGBP1) interacts with the 5' region of C/EBP beta mRNA and regulates translation of C/EBP beta isoforms. Nucleic Acids Res 1999;27:4517-4525. (Pubitemid 29533195)
99. Zinszner H, Sok J, Immanuel D, Yin Y, Ron D. TLS (FUS) binds RNA in vivo and engages in nucleo-cytoplasmic shuttling. J Cell Sci 1997;110:1741-1750. (Pubitemid 27352853)
100. Perrotti D, Iervolino A, Cesi V, et al. BCR-ABL prevents c-Jun-mediated and proteasome-dependent FUS (TLS) proteolysis through a protein kinase C beta II-dependent pathway. Mol Cell Biol 2000;20:6159-6169. (Pubitemid 30613063)
101. Ambros V. The functions of animal microRNAs. Nature 2004;431:350-355. (Pubitemid 39265675)
102. Bueno MJ, de Castro IP, de Cedron MG, et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogeneexpression. CancerCell 2008;13:496-506. (Pubitemid 351763902)
103. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003;115:787-798. (Pubitemid 38058492)
104. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005;435:839-843. (Pubitemid 40839736)
105. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006;103:2257-2261. (Pubitemid 43271657)
106. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-838. (Pubitemid 40839735)
107. Stegmaier K, Ross KN, Colavito SA, O'Malley S, Stockwell BR, Golub TR. Gene expression-based high-throughput screening (GE-HTS) and application to leukemia differen-tiation. Nat Genet 2004;36:257-263. (Pubitemid 38282750)
108. Eiring AM, Harb JG, Neviani P, et al. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell 2010;140:652-665.
109. Koschmieder S, Gottgens B, Zhang P, et al. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABLleukemogenesis. Blood 2005;105:324-334. (Pubitemid 40053100)
110. San Jose-Eneriz E, Roman-Gomez J, Jimenez-Velasco A, et al. MicroRNA expression profiling in imatinib-resistant chronic myeloid leukemia patients without clinically signifi-cantABL1-mutations. Mol Cancer 2009;8:69.
111. Agirre X, Jimenez-Velasco A, Jose-Eneriz ES, et al. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34(+) cells increases USF2-mediated cell growth. Mol Cancer Res 2008;6:1830-1840.
112. Heo I, Joo C, Cho J, Ha M, Han JJ, Kim VN. Lin28 mediates the terminal uridylation of Let-7 precursor microRNA. Mol Cell 2008;32:276-284.
113. Newman MA, Thomson JM, Hammond SM. Lin-28 interaction with the Let-7 precursor loop mediates regulated microRNA processing. RNA 2008;14:1539-1549.
114. Rybak A, Fuchs H, Smirnova L, et al. A feedback loop comprising lin-28 and let-7 controls pre-let-7 maturation during neural stem-cell commitment. Nat Cell Biol 2008; 10:987-993.
115. Viswanathan SR, Daley GQ, Gregory RI. Selective blockade of MicroRNA processing by Lin28. Science 2008;320:97-100. (Pubitemid 351490762)
116. Viswanathan SR, Powers JT, Einhorn W, et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet 2009;41:843-848.
117. Schotte D, Chau JCK, Sylvester G, et al. Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia. Leukemia 2009;23: 313-322.
118. Sampson VB, Rong NH, Han J, et al. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 2007;67:9762-9770. (Pubitemid 47621223)
119. Johnson SM, Grosshans H, ShingaraJ, et al. RAS is regulated by the let-7 microRNA family. Cell 2005;120:635-647. (Pubitemid 40343076)
120. Cohen MH, Johnson JR, Pazdur R. US food and drug administration drug approval summary: conversion of imatinib mesylate (ST1571; Gleevec) tablets from accelerated approval to full approval. Clin Cancer Res 2005;11:12-19. (Pubitemid 40075773)
121. Perrotti D, Neviani P. ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelo-genous leukaemia. Br J Cancer 2006;95:775-781. (Pubitemid 44500626)
122. Flamant S, Ritchie W, Guilhot J, et al. Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia. Haematologica 2010;95:1325-1333.